Clinical Trials Browser

Phase 1/2 × Neoplasms × lirilumab × Clear all

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

Neoplasms

NCT01714739 2023-02-02

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

Phase 1/2 Completed

337 enrolled 42 charts

Neoplasms